Biogen Idec (BIIB) volatility deceases as shares rally 7% on positive top-line results

Biogen Idec (Nasdaq: BIIB) is recently up 7% following positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis. Goldman Sachs say's "Oral MS drug better than expected, but tolerability will be crucial." May 83 calls are active on low option implied volatility of 25; below its six-month average of 28 according to Track Data.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
• Ishares Msci South Korea Capped Etf (EWY) call put ratio 2.4 calls to 1 put as share price up 1.9%
• Pembina Pipeline (PBA) 3900 contracts of September 55 calls active